ArticleScientific reports2025
scATAC-seq generates more accurate and complete regulatory maps than bulk ATAC-seq.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Multi-Omics-Guided Design and Safety Engineering of Nucleic Acid Therapeutics: From Molecular Perturbation to Predictive Toxicology and Precision Translation.Chemical biology & drug design · 2026Review
- scATAnno: Automated Cell Type Annotation for Single-cell ATAC-seq Data.Genomics, proteomics & bioinformatics · 2026Article
- Single-cell Technologies in Atherosclerosis: Uncovering Cellular Heterogeneity, Mechanisms, and Therapeutic Opportunities.Current atherosclerosis reports · 2026Review
- DecipheringBioinformatics advances · 2026Article
- Recent advances in methodologies of epigenomics.Epigenomics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Bulk ATAC-seq assays have been used to map and profile the chromatin accessibility of regulatory elements such as enhancers, promoters, and insulators. This has provided great insight into the regulation of gene expression in many cell types in a variety of organisms. To date, ATAC-seq has most often been used to provide an average evaluation of chromatin accessibility in populations of cells. The development of a single cell approach (scATAC-seq) assay enables researchers to evaluate chromatin accessibility in individual cells and identify sub-groups in mixed populations of cells. To investigate the full potential of single-cell epigenomic data, we have comprehensively compared the information derived from bulk ATAC-seq and scATAC-seq in populations of cells. We found that the chromatin architecture signal is the same using bulk ATAC-seq and scATAC-seq to analyse aliquots of the same cell population. However, scATAC-seq provides substantially higher data quality compared to bulk ATAC-seq improving the sensitivity to detect relatively weak, but functionally important ATAC-seq signals. Furthermore, we found that scATAC-seq identified differences in what was previously assumed to be a homogenous population of cells. Finally, we determined the number of cells required to generate aggregated open chromatin profiles from single cells and to identify biologically meaningful clusters after pseudo-bulking of data. This study illustrates the added value of using scATAC-seq rather than bulk ATAC-seq in evaluating both homogeneous and heterogeneous populations of cells. This paper provides a comprehensive guide on the benefits of using scATAC-seq data to study gene regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.